Literature DB >> 12818575

Identification of the genotypes causing hypertrophic cardiomyopathy in northern Sweden.

Stellan Mörner1, Pascale Richard, Elsadig Kazzam, Urban Hellman, Bernard Hainque, Ketty Schwartz, Anders Waldenström.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a heterogenous disease, with variable genotypic and phenotypic expressions, often caused by mutations in sarcomeric protein genes. The aim of this study was to identify the genotypes and associated phenotypes related to HCM in northern Sweden. In 46 unrelated individuals with familial or sporadic HCM, mutation analysis of eight sarcomeric protein genes was performed; the cardiac beta-myosin heavy chain, cardiac myosin-binding protein C, cardiac troponin T, alpha-tropomyosin, cardiac essential and regulatory myosin light chains, cardiac troponin I and cardiac alpha-actin. A total of 11 mutations, of which six were novel ones, were found in 13 individuals. Seven mutations were located in the myosin-binding protein C gene, two in the beta-myosin heavy chain gene and one in the regulatory myosin light chain and troponin I genes, respectively. This is the first Swedish study, where a population with HCM has been genotyped. Mutations in the cardiac myosin-binding protein C gene were the most common ones found in northern Sweden, whereas mutations in the beta-myosin heavy chain gene were less frequent than previously described. There are differences in the phenotypes mediated by these genes characterised by a more late-onset disease for the myosin-binding protein C gene mutations. This should be taken into consideration, when evaluating clinical findings in the diagnosis of the disease, especially in young adults in families with HCM, where penetrance can be expected to be incomplete in the presence of a myosin-binding protein C gene mutation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12818575     DOI: 10.1016/s0022-2828(03)00146-9

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  38 in total

1.  Clinical assessment incorporating a personal genome.

Authors:  Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

2.  Familial hypertrophic cardiomyopathy can be characterized by a specific pattern of orientation fluctuations of actin molecules .

Authors:  J Borejdo; D Szczesna-Cordary; P Muthu; N Calander
Journal:  Biochemistry       Date:  2010-06-29       Impact factor: 3.162

3.  Stability and kinetic properties of C5-domain from myosin binding protein C and its mutants.

Authors:  Carlo Guardiani; Fabio Cecconi; Roberto Livi
Journal:  Biophys J       Date:  2007-10-26       Impact factor: 4.033

4.  Gene expression patterns in transgenic mouse models of hypertrophic cardiomyopathy caused by mutations in myosin regulatory light chain.

Authors:  Wenrui Huang; Katarzyna Kazmierczak; Zhiqun Zhou; Vanessa Aguiar-Pulido; Giri Narasimhan; Danuta Szczesna-Cordary
Journal:  Arch Biochem Biophys       Date:  2016-02-22       Impact factor: 4.013

5.  Effect of a myosin regulatory light chain mutation K104E on actin-myosin interactions.

Authors:  D Duggal; J Nagwekar; R Rich; W Huang; K Midde; R Fudala; H Das; I Gryczynski; D Szczesna-Cordary; J Borejdo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-03-13       Impact factor: 4.733

Review 6.  Pseudophosphorylation of cardiac myosin regulatory light chain: a promising new tool for treatment of cardiomyopathy.

Authors:  Sunil Yadav; Danuta Szczesna-Cordary
Journal:  Biophys Rev       Date:  2017-01-25

7.  The role of sarcomere gene mutations in patients with idiopathic dilated cardiomyopathy.

Authors:  Daniel Vega Møller; Paal Skytt Andersen; Paula Hedley; Mads Kristian Ersbøll; Henning Bundgaard; Johanna Moolman-Smook; Michael Christiansen; Lars Køber
Journal:  Eur J Hum Genet       Date:  2009-03-18       Impact factor: 4.246

Review 8.  Hereditary heart disease: pathophysiology, clinical presentation, and animal models of HCM, RCM, and DCM associated with mutations in cardiac myosin light chains.

Authors:  Sunil Yadav; Yoel H Sitbon; Katarzyna Kazmierczak; Danuta Szczesna-Cordary
Journal:  Pflugers Arch       Date:  2019-01-31       Impact factor: 3.657

Review 9.  A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management.

Authors:  Kyla E Dunn; Colleen Caleshu; Allison L Cirino; Carolyn Y Ho; Euan A Ashley
Journal:  Circ Cardiovasc Genet       Date:  2013-02

10.  Malignant familial hypertrophic cardiomyopathy D166V mutation in the ventricular myosin regulatory light chain causes profound effects in skinned and intact papillary muscle fibers from transgenic mice.

Authors:  W Glenn L Kerrick; Katarzyna Kazmierczak; Yuanyuan Xu; Yingcai Wang; Danuta Szczesna-Cordary
Journal:  FASEB J       Date:  2008-11-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.